When you ask though what happens if you hit one outcome and not the other. That’s surely a difficult situation to be in. We want to understand why that happened. If that were to happen where the irregularities in CDR Sum of Boxes that could explain it what did the rest of the secondaries look like. Always best to hit all of your outcomes in a clinical trial. Feeling that you want to hit your primary in as many secondaries as possible. So let’s wait and see.
Joe Fletcher: Thanks Umer. Lois, next question.
Operator: That question is from Mohit Bansal from Wells Fargo. Please go ahead.
Mohit Bansal: Great. Thank you very much for taking my question. Maybe a question regarding your next-generation Alzheimer’s drug. I cannot pronounce the name remternetug I’ll learn it. But how does it differ or similar versus donanemab? Asking — because I mean you’re running a Phase III trial with subcu here. So what would be the read through for this particular asset based on the outcome of donanemab Phase III trial?
Joe Fletcher: Dan, do you want to talk a little bit about remternetug?
Dan Skovronsky: Yes. I think ,you’ve got it basically, right. Remternetug is a new medicine, a new molecule, but it’s an antibody against the same type of epitope that donanemab has which is this N3pG form of a beta. So a very equivalent mechanism of action. Maybe a little better potency and certainly better drug properties including, no ADAs and formulation things. So the rationale here is to give improved dosing options to patients. Could we get even faster plaque clearance, could it be with fewer doses, could it be subcutaneous. Those are the types of things, that we’re currently exploring. The Phase III is designed with a bit of a run-in, were in that portion right now to finalize our dosing strategy and then expand it. Obviously, if donanemab is disappointing there would be read-through remternetug. On the other hand, if donanemab exceeds expectations, I would expect that to read through as well.
Joe Fletcher: Thank you, Mohit, Next question.
Operator: The next question is Evan Seigerman from BMO. Please go ahead.
Evan Seigerman: Hi, guys. Thank you so much for taking the questions. While much of the discussion on Medicare coverage in Alzheimer’s, we know that Medicare really doesn’t pay for obesity drugs. Can you just talk about your efforts to help Medicare patients get coverage for obesity drugs including, potentially Mounjaro if approved. Maybe add some parameters around, what that additional population could look like from a revenue opportunity perspective. Thank you.
Joe Fletcher: Thanks, Evan for the question. I’ll hand over to Mike. Mike, do you want to talk about the potential for Medicare to cover obesity?
Mike Mason: Okay. Sure. Yes, good question. I mean, it’s going to take less late action in order to allow diabetes medications to be covered on Medicare Part D. So there is the Treat and Reduce Obesity Act. The acronym for that is TROA. And there’s a large growing bipartisan support for TROA, a little over 100 congressmen, senators, people senators are behind the program. And it’s growing more and more support across Washington. We’re eager to see an advanced list process. It would be great for the company country. America needs to take action and drastic reduce the number of people in the DC and this oscillation would be an important step for this goal. We’ll support the translation and continue to work, to advocate for it.
Joe Fletcher: Thanks, Mike. Lois, next question.
